Covalon Technologies (Covalon Technologies) EBIT : $-4.18 Mil (TTM As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Covalon Technologies EBIT?

Covalon Technologies's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was $-1.10 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $-4.18 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Covalon Technologies's annualized ROC % for the quarter that ended in Dec. 2023 was -52.74%. Covalon Technologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -65.53%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Covalon Technologies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -28.53%.

Covalon Technologies EBIT Historical Data

The historical data trend for Covalon Technologies's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Covalon Technologies EBIT Chart

Covalon Technologies Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

EBIT

Get a 7-Day Free Trial

-6.23

-5.58

0.66

-6.85

-3.35

Covalon Technologies Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT	Get a 7-Day Free Trial															-0.26	-0.53	-0.44	-2.12	-1.10

Competitive Comparison of Covalon Technologies's EBIT

For the Biotechnology subindustry, Covalon Technologies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Covalon Technologies's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Covalon Technologies's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Covalon Technologies's EV-to-EBIT falls into.

Covalon Technologies EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.18 Mil.

Covalon Technologies (OTCPK:CVALF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Covalon Technologies's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-4.388 * ( 1 - 0% )	/	( (8.603	+	8.038)	/ 2 )
=	-4.388	/	8.3205
=	-52.74 %

where

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	18.403	-	3.3	-	( 6.5	-	max(0, 3.835	-	15.735	+	6.5	))
=	8.603

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	16.612	-	2.393	-	( 6.181	-	max(0, 2.885	-	13.887	+	6.181	))
=	8.038

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Covalon Technologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-4.388	/	( ( (1.244 + max(5.875, 0))	+	(1.151 + max(5.123, 0)) )	/	2 )
=	-4.388	/	( ( 7.119	+	6.274 )	/	2 )
=	-4.388	/	6.6965
=	-65.53 %

where Working Capital is:

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(4.554	+	4.394	+	0.287)	-	(3.3	+	0.06	+	0)
=	5.875

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(2.587	+	4.509	+	0.435)	-	(2.393	+	0.015	+	0)
=	5.123

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Covalon Technologies's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	-4.184	/	14.665
	=	-28.53 %

Covalon Technologies EBIT Related Terms

Thank you for viewing the detailed overview of Covalon Technologies's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Covalon Technologies (Covalon Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Covalon Technologies Ltd (OTCPK:CVALF) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

COV:Canada

Address

1660 Tech Avenue, Unit 5, Mississauga, ON, CAN, L4W 5S7

Website

https://www.covalon.com

Covalon Technologies Ltd is principally engaged in the business of developing, licensing, and selling medical technologies. The company develops advanced wound care line which is designed for the treatment of a wide range of wounds; and infection prevention products such as MediClear PreOp which is a breathable, transparent, self-adhesive silicone barrier film that conforms to the contours of the body. It also develops perioperative care products. The company generates its revenue through development contracts, licensing agreements, and distribution contracts, and sales.